Group 1 - Heng Rui Pharmaceutical has set the final price for its H-share issuance at HKD 44.05 per share, which is the upper limit of the previously expected price range [1] - The H-shares will officially be listed on the Hong Kong Stock Exchange on May 23, with cornerstone investors including GIC, Invesco, UBS Global Asset Management, Hillhouse Capital, and Boyu Capital [1] - The purpose of this H-share issuance is to further promote the company's global strategic layout, enhance its international brand image, and strengthen connections with overseas capital markets [1] Group 2 - Chao Hong Ji is planning to issue H-shares for listing on the Hong Kong Stock Exchange, with details and plans yet to be finalized [2] - The company has experienced significant stock price fluctuations, with a cumulative increase of over 20% in closing prices over three consecutive trading days [2] - This move is aimed at expanding the international market and enhancing brand influence, which is expected to positively impact the company's long-term development [2] Group 3 - ZTO Express reported a revenue of CNY 10.892 billion for Q1 2025, representing a year-on-year increase of 9.4% [3] - The gross profit for the same period was CNY 2.689 billion, a decrease of 10.4% year-on-year, while the adjusted net profit was CNY 2.259 billion, up 1.6% year-on-year [3] - The company completed a total of 8.5 billion packages in Q1, marking a year-on-year growth of 19.1% [3] Group 4 - Hangpin Life Technology announced the acquisition of 1 million shares of China Petroleum at an average price of HKD 6.285 per share, totaling HKD 6.285 million [4] - This acquisition is part of the company's diversification strategy, aimed at increasing investment returns and financial flexibility [4] - The shares acquired will be held as a long-term investment to achieve capital appreciation and potential dividend income [4]

Group 1: IPO Market Overview - The Hong Kong stock market is experiencing a new wave of IPO activity, with total fundraising reaching HKD 145 billion in the past year, a year-on-year increase of 2.7 times [1][2] - The top ten IPOs, primarily from mainland companies, contributed 75% of the total fundraising, with notable leaders being CATL and Midea Group [2][3] - As of May 21, 2025, 76 new stocks have been listed, with 23 companies going public this year alone, raising a total of HKD 653 billion [2] Group 2: Key Players and Fundraising - CATL and Midea Group led the fundraising efforts with HKD 410 billion and HKD 356.66 billion respectively, marking them as the top fundraisers for 2024 and 2025 [2][4] - Other significant players in the second tier include Horizon Robotics, SF Express, and China Resources Beverage, each raising over HKD 50 billion [2][4] - The third tier consists of consumer-related companies like Mixue Group and Chifeng Gold, raising between HKD 20 billion and HKD 40 billion [3][4] Group 3: Globalization and Strategic Moves - Chinese companies are accelerating their global expansion through the "A+H" dual capital market strategy, which is crucial for their international growth [5][6] - Leading companies in various sectors, including pharmaceuticals and consumer electronics, are planning to list in Hong Kong to enhance their global presence [6][7] - The automotive sector is also seeing increased activity, with companies like Seres and Chery Motors planning to raise funds through IPOs in Hong Kong [8] Group 4: Capital Inflows and Market Dynamics - The weakening US dollar has led to increased capital inflows into the Hong Kong market, as investors seek to buy Chinese assets [9][10] - The Hong Kong Monetary Authority has injected over HKD 1.16 billion into the market to support the Hong Kong dollar, reflecting strong demand for stocks [9] - The successful IPOs of companies like CATL have created a "money-making effect," encouraging more mainland companies to pursue listings in Hong Kong [10] Group 5: Regulatory Environment - The Hong Kong regulatory framework is evolving to facilitate the listing process for mainland companies, including the introduction of a "special line" for tech and biotech firms [11][12] - Recent changes have lowered the minimum requirements for H-share listings, making it easier for companies to access the Hong Kong capital market [12]

Core Insights - The article discusses recent activities on the Hong Kong Stock Exchange, including companies filing for IPOs, passing hearings, and listing. Group 1: Companies Filing for IPOs - Two companies filed for IPOs: Dongfang Yanmei and NobiKan Technology [2][3] - Dongfang Yanmei focuses on regenerative medical devices and special medical foods, with projected revenues of RMB 128.82 billion and RMB 145.20 billion for 2023 and 2024, respectively, and net losses of RMB 63.51 million and RMB 69.38 million [2] - NobiKan Technology specializes in AI technologies and digital twin applications, with expected revenues of approximately RMB 253 million, RMB 364 million, and RMB 403 million from 2022 to 2024, and net profits of RMB 63.16 million, RMB 88.57 million, and RMB 115 million during the same period [3] Group 2: Companies Passing Hearings - Three companies passed the hearing: Mirxes, Shouhui Group, and MetaLight Inc. [4][6] - Mirxes, a miRNA technology company, aims to provide disease screening solutions in Asia, with revenues of approximately USD 17.76 million, USD 24.19 million, and USD 20.28 million from 2022 to 2024 [5] - Shouhui Group is a leading online insurance intermediary in China, with revenues of RMB 806 million, RMB 1.634 billion, and RMB 1.387 billion from 2022 to 2024 [7] - MetaLight Inc. operates a real-time bus information platform, achieving revenues of RMB 135 million, RMB 175 million, and RMB 206 million from 2022 to 2024 [8] Group 3: Companies Launching IPOs - Four companies are currently in the process of launching IPOs: Green Tea Group, CATL, Heng Rui Medicine, and Mirxes [9][10][11][12] - Green Tea Group's IPO was priced at HKD 7.19 per share, with a market capitalization of approximately HKD 4.236 billion upon listing [14] - CATL's IPO was priced at HKD 263.00 per share, with a subscription rate of nearly 120 times [10] - Heng Rui Medicine plans to offer shares at a price not exceeding HKD 44.05, with expectations to list on May 23, 2025 [11]

Major Events - Heng Rui Medicine (01276) plans to globally issue 224.5 million H-shares, expected to be listed on May 23 [1] - MIRXES-B (02629) will conduct an IPO from May 15 to May 20, aiming to globally issue 46.62 million shares [1] - Green Tea Group (06831) received 317.54 times subscription for its public offering in Hong Kong, with a final issue price of HKD 7.19 per share [1] - CSPC Pharmaceutical Group (01093) signed an exclusive licensing agreement with Cipla for the commercialization of Irinotecan Liposome Injection in the United States [1] - CanSino Biologics (06185) received clinical trial approval for its inhaled tuberculosis booster vaccine in Indonesia [1] - Fuhong Hanlin (02696) has been included in the MSCI Global Small Cap Index [1] - Financial One Account (06638) received a privatization offer from Ping An Group (02318) at a premium of approximately 23.10% [1] Financial Reports - Alibaba-W (09988) reported revenue and net profit growth for the fiscal year 2025, with net profit attributable to shareholders increasing by 62% to CNY 129.47 billion [1] - NetEase-S (09999) announced Q1 results with net profit attributable to shareholders at CNY 10.301 billion, a year-on-year increase of 34.94%, and a quarterly dividend of USD 0.135 per share [1] - Geely Automobile (00175) released Q1 results showing a significant increase in profit attributable to shareholders of CNY 5.672 billion, up 263.59% year-on-year [1] - Beike-W (02423) reported a total transaction volume growth of 34.0% year-on-year in Q1, with net revenue increasing by 42.4% [1] - Minhua Holdings (01999) announced annual results with profit attributable to shareholders of HKD 2.063 billion, a decrease of 10.41% year-on-year [1] - Shoucheng Holdings (00697) reported Q1 results with profit attributable to shareholders of HKD 213 million, an increase of 80.5% year-on-year [1] - Fourth Paradigm (06682) showed strong performance in core business with total revenue of CNY 1.077 billion in Q1, a year-on-year growth of 30.1% [1]

Investment Rating - The report assigns an IPO-specific rating of 6.1, based on various criteria including company operations, industry outlook, valuation, and market sentiment [6][8]. Core Insights - The company, Heng Rui Pharmaceutical, is a leading innovative pharmaceutical enterprise rooted in China, with projected revenues of 27.985 billion RMB (+22.6%) and a net profit of 6.337 billion RMB (+47.3%) for 2024. The gross margin is expected to improve by 1.6 percentage points to 86.2% [1]. - The core growth driver is the revenue from innovative drugs, which is expected to increase from 38.1% of total revenue in 2022 to 46.3% in 2024, supported by key products like PD-L1&TGF-β and HER2ADC [1]. - The global pharmaceutical market is projected to grow from $1,472.3 billion in 2023 to $1,938.7 billion by 2028, with a CAGR of 5.7%. The Chinese pharmaceutical market is expected to grow from 1,618.3 billion RMB in 2023 to 2,342.0 billion RMB by 2028, with a CAGR of 7.7% [2]. - The company has a strong R&D capability, with an investment of 8.2 billion RMB in 2024, representing 29.4% of total revenue, and cumulative R&D investment exceeding 44 billion RMB [3]. - The company has a robust commercialization capability with a sales and marketing team of approximately 9,000, covering over 22,000 hospitals and 200,000 retail pharmacies in China [4]. Company Overview - Heng Rui Pharmaceutical is positioned as a global leader in innovative pharmaceuticals, focusing on unmet medical needs across various therapeutic areas, including oncology, metabolic and cardiovascular diseases, immunology, and neuroscience [3]. - The company has over 110 commercialized drugs, including 19 new molecular entities and four other innovative drugs [3]. - The financial health of the company is strong, with a debt-to-asset ratio of 8% and no interest-bearing debt, allowing for sustainable R&D investments [4].

集团估计，经扣除承销佣金及其他集团就全球发售应付的估计费用后，集团将自全球发售获得募集资金 净额约94.58亿港元(假设发售价为每股H股42.75港元，即本招股章程所述发售价范围的中位数，并假设 发售量调整权及超额配股权未获行使)或125.28亿港元(倘发售量调整权及超额配股权获悉数行使)。集团 拟将全球发售募集资金净额用于以下用途：约75%将用于集团的研发计划;约15%将用于在中国和海外市 场建设新的生产和研发设施;余下约10%将用作集团的营运资金及其他一般企业用途。 集团已与GIC、Invesco Advisers、UBS AM Singapore等基石投资者订立基石投资协议，据此，基石投资 者已同意遵照若干条件，按发售价认购或促使其指定实体认购若干数目的发售股份(向下约整至最接近 每手200股H股的完整买卖单位)，总金额为5.33亿美元(假设发售价为每股发售股份42.75港元(即发售价 范围的中位数)。 对创新的这一执着追求，从集团的资金投入中可见一斑，2024年集团的研发投入(包括研发费用及资本 化研发支出)占总收入的百分比达29.4%。此外，集团致力于为股东带来可观的回报。自A股上市以来， 集团的累 ...

Investment Rating - The report maintains a "Buy" rating for the company [3]. Core Insights - The company achieved a revenue of 13.6 billion yuan in the first half of 2024, representing a year-on-year increase of 21.8%, and a net profit of 3.43 billion yuan, up 48.7% year-on-year [2][3]. - The innovative drug business generated 6.612 billion yuan in revenue, a growth of 33% year-on-year, while the generic drug business saw a slight decline due to centralized procurement impacts [3]. - The company confirmed a 160 million euro upfront payment from Merck Healthcare as revenue, indicating recognition of its innovation capabilities by international pharmaceutical companies [3]. Revenue and Profit Forecast - The company is projected to achieve net profits of 6.023 billion yuan, 7.233 billion yuan, and 8.591 billion yuan for the years 2024, 2025, and 2026 respectively, with upward adjustments of 16.6%, 16.3%, and 15.3% [3][4]. - The current price-to-earnings (P/E) ratios are forecasted to be 46, 38, and 32 for the years 2024, 2025, and 2026 respectively [4][10]. International Expansion - The company is actively pursuing internationalization by licensing its GLP-1 class innovative drugs to Hercules in the U.S. for approximately 6 billion USD, while also acquiring a 19.9% equity stake in Hercules [3]. - The company is conducting multiple overseas clinical trials, with three ADC products receiving fast-track designation from the U.S. FDA in the first half of 2024 [3]. Financial Metrics - The company’s revenue is expected to grow from 27.221 billion yuan in 2024 to 34.681 billion yuan in 2026, with a compound annual growth rate (CAGR) of approximately 15.72% [4][7]. - The gross profit margin is projected to improve from 84.6% in 2023 to 85.9% in 2026 [9].